CoChat
Sign Up
Cited by 125SARS-CoV-2 and COVID-19 ResearchImmune responses and vaccinationsAnimal Virus Infections Studies

The DOI matches its Crossref record; 21 of the 22 references it cites were found in a registry or an index.

Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice

Open access
Spencer, Alexandra J., McKay, Paul F., Belij-Rammerstorfer, Sandra, Ulaszewska, Marta, Bissett, Cameron D., Hu, Kai, Samnuan, Karnyart, Blakney, Anna K., Wright, Daniel, Sharpe, Hannah R., Gilbride, Ciaran, Truby, Adam, Allen, Elizabeth R., Gilbert, Sarah C., Shattock, Robin J., Lambe, Teresa·2021·Nature Communications
DOI 10.1038/s41467-021-23173-1PMC PMC8129084

Published version of a preprint

Open this paper in CoChat — free accountOpen PDF

Abstract

Abstract Several vaccines have demonstrated efficacy against SARS-CoV-2 mediated disease, yet there is limited data on the immune response induced by heterologous vaccination regimens using alternate vaccine modalities. Here, we present a detailed description of the immune response, in mice, following vaccination with a self-amplifying RNA (saRNA) vaccine and an adenoviral vectored vaccine (ChAdOx1 nCoV-19/AZD1222) against SARS-CoV-2. We demonstrate that antibody responses are higher in two-dose heterologous vaccination regimens than single-dose regimens. Neutralising titres after heterologous prime-boost were at least comparable or higher than the titres measured after homologous prime boost vaccination with viral vectors. Importantly, the cellular immune response after a heterologous regimen is dominated by cytotoxic T cells and Th1 + CD4 T cells, which is superior to the response induced in homologous vaccination regimens in mice. These results underpin the need for clinical trials to investigate the immunogenicity of heterologous regimens with alternate vaccine technologies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-23173-1

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Antibody responses following ChAd and saRNA vaccination. Antibody responses were measured in the serum of CD1 (n = 8) and BALB/c (n = 6) mice collected 3 weeks after the final immunization. Graphs show SARS-CoV-2 spike-specific IgG (A), IgM and IgA (B), and IgG avidity (C) measured by ELISA, and SARS-CoV-2-pseudotyped virus neutralization (IC50) (D). Individual mice are represented by a single data point; bars represent the median response in each group (CD1 n = 8; BALB/c n = 6). Data in each graph were analysed with a one-way ANOVA Kruskal–Wallis test followed by post hoc Dunn’s multiple comparisons test to compare differences between vaccination groups; p-values indicate significant differences (p < 0.05) between groups.
Fig. 1 Antibody responses following ChAd and saRNA vaccination. Antibody responses were measured in the serum of CD1 (n = 8) and BALB/c (n = 6) mice collected 3 weeks after the final immunization. Graphs show SARS-CoV-2 spike-specific IgG (A), IgM and IgA (B), and IgG avidity (C) measured by ELISA, and SARS-CoV-2-pseudotyped virus neutralization (IC50) (D). Individual mice are represented by a single data point; bars represent the median response in each group (CD1 n = 8; BALB/c n = 6). Data in each graph were analysed with a one-way ANOVA Kruskal–Wallis test followed by post hoc Dunn’s multiple comparisons test to compare differences between vaccination groups; p-values indicate significant differences (p < 0.05) between groups.CC BY · PubMed Central
Fig. 2 SARS-CoV-2 spike-specific IgG subclasses following ChAd and saRNA vaccination. For detection of IgG subclasses in the serum of CD1 (n = 8) and BALB/c (n = 6) mice, each sample was diluted to 1 IgG ELISA Unit. Graphs show optical density measured against each IgG subclass where individual data points were expressed as an OD and shown here as scatter dot plots with bars showing the median (A), followed by the heatmap summary representation with median response in each group to each IgG subclass (B). Individual mice are represented by a single data point, bars represent the median response in each group (CD1 n = 8; BALB/c n = 6) with serum collected 3 weeks after the final vaccination. Data in each graph was analysed with a one-way ANOVA Kruskal–Wallis followed by a post hoc Dunn’s multiple comparison test to compare differences between vaccination groups; p-values indicate significant difference (p < 0.05) between groups.
Fig. 2 SARS-CoV-2 spike-specific IgG subclasses following ChAd and saRNA vaccination. For detection of IgG subclasses in the serum of CD1 (n = 8) and BALB/c (n = 6) mice, each sample was diluted to 1 IgG ELISA Unit. Graphs show optical density measured against each IgG subclass where individual data points were expressed as an OD and shown here as scatter dot plots with bars showing the median (A), followed by the heatmap summary representation with median response in each group to each IgG subclass (B). Individual mice are represented by a single data point, bars represent the median response in each group (CD1 n = 8; BALB/c n = 6) with serum collected 3 weeks after the final vaccination. Data in each graph was analysed with a one-way ANOVA Kruskal–Wallis followed by a post hoc Dunn’s multiple comparison test to compare differences between vaccination groups; p-values indicate significant difference (p < 0.05) between groups.CC BY · PubMed Central
Fig. 3 Breadth of T-cell response measured by ELISpot. Graphs represent the total spike-specific IFNγ response (sum of peptide pools) measured in outbred CD1 (n = 8) (A) or inbred BALB/c (n = 6) (B) 3 weeks after the final vaccination. Pie charts represent the response to each peptide pool as a proportion of total response. Data points represent individual mice and bars represent the median response in each group. Data in each graph were analysed with a two-way ANOVA Friedman test and post hoc Dunn’s multiple comparison to compare between vaccination regimens, p-values indicate significant difference (p < 0.05) between groups.
Fig. 3 Breadth of T-cell response measured by ELISpot. Graphs represent the total spike-specific IFNγ response (sum of peptide pools) measured in outbred CD1 (n = 8) (A) or inbred BALB/c (n = 6) (B) 3 weeks after the final vaccination. Pie charts represent the response to each peptide pool as a proportion of total response. Data points represent individual mice and bars represent the median response in each group. Data in each graph were analysed with a two-way ANOVA Friedman test and post hoc Dunn’s multiple comparison to compare between vaccination regimens, p-values indicate significant difference (p < 0.05) between groups.CC BY · PubMed Central
Fig. 4 Phenotype of the T-cell response following vaccination. CD1 (n = 8) and BALB/c (n = 6) splenocytes collected 3 weeks after the final vaccination were stimulated for 6 h with pools of overlapping SARS-CoV-2 peptides prior to staining for effector and memory T cells markers and intracellular cytokines. A Graphs show the frequency of the spike-specific CD4+ T-cell responses (left) in CD1 (top panel) and BALB/c mice (bottom panel); heatmaps (middle) show the proportion of the response producing each cytokine and total number of antigen-specific cells of a T effector (Teff), T effector memory (Tem) or T central memory (Tcm) phenotype (right). B Graphs show the frequency of the spike-specific CD8+ T-cell responses (left) in CD1 (top panel) and BALB/c mice (bottom panel); heatmaps (middle) show the proportion of the response producing each cytokine and total number of antigen-specific cells of a T effector (Teff), T effector memory (Tem) or T central memory (Tcm) phenotype (right). Data points indicate individual mice; bars represent the median response in each group. Total numbers of each population are displayed in Supplementary Fig S3C. Data in each graph were analysed with a two-way ANOVA comparing the effect of vaccination regimen and cytokine production or T-cell phenotype, followed by a post hoc Tukey’s multiple comparison test to compare between vaccination regimens; p-values showing overall differences between vaccination groups (p < 0.05) are indicated on the graph.
Fig. 4 Phenotype of the T-cell response following vaccination. CD1 (n = 8) and BALB/c (n = 6) splenocytes collected 3 weeks after the final vaccination were stimulated for 6 h with pools of overlapping SARS-CoV-2 peptides prior to staining for effector and memory T cells markers and intracellular cytokines. A Graphs show the frequency of the spike-specific CD4+ T-cell responses (left) in CD1 (top panel) and BALB/c mice (bottom panel); heatmaps (middle) show the proportion of the response producing each cytokine and total number of antigen-specific cells of a T effector (Teff), T effector memory (Tem) or T central memory (Tcm) phenotype (right). B Graphs show the frequency of the spike-specific CD8+ T-cell responses (left) in CD1 (top panel) and BALB/c mice (bottom panel); heatmaps (middle) show the proportion of the response producing each cytokine and total number of antigen-specific cells of a T effector (Teff), T effector memory (Tem) or T central memory (Tcm) phenotype (right). Data points indicate individual mice; bars represent the median response in each group. Total numbers of each population are displayed in Supplementary Fig S3C. Data in each graph were analysed with a two-way ANOVA comparing the effect of vaccination regimen and cytokine production or T-cell phenotype, followed by a post hoc Tukey’s multiple comparison test to compare between vaccination regimens; p-values showing overall differences between vaccination groups (p < 0.05) are indicated on the graph.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

Sorted by citations

See all 125

Related

Metadata

Authors
Spencer, A. J., McKay, P. F., Belij-Rammerstorfer, S., Ulaszewska, M., Bissett, C. D., Hu, K., Samnuan, K., Blakney, A. K., Wright, D., Sharpe, H. R., Gilbride, C., Truby, A., Allen, E. R., Gilbert, S. C., Shattock, R. J., & Lambe, T.
Affiliations
  • University of Oxford (GB)
  • Imperial College London (GB)
Corresponding author
Spencer, Alexandra J.
ORCID
Venue
Nature Communications
Publisher
Springer Science and Business Media LLC
Published
2021-05-17
Volume
12
Issue
1
Pages
2893-2893
ISSN
2041-1723 (ISSN-L)
DOI
10.1038/s41467-021-23173-1
PMC
PMC8129084
OpenAlex
W3160352759
Cited by
125
References
22
Citations by year
2026: 3 · 2025: 6 · 2024: 14 · 2023: 16 · 2022: 44 · 2021: 42
FWCI
9.19
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Spiral (Imperial College London) (submittedVersion, cc-by)
Funders
  • UK Research and Innovation (MC_PC_19055)
  • National Institute for Health and Care Research (COV19 OxfordVacc-01, COVID-19, OxfordVacc-01, COV19OxfordVaccine01, MC_PC_19055)
  • University of Oxford
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
  • Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Keywords
heterologous vaccination, self-amplifying RNA vaccine, adenovirus vector vaccine, SARS-CoV-2, COVID-19 vaccines, prime-boost vaccination, antibody response, neutralizing antibodies, cell-mediated immunity, cytotoxic T lymphocytes, Th1 cells, immunogenicity
MeSH terms
Immunogenicity, Vaccine, COVID-19, SARS-CoV-2, COVID-19 Vaccines, ChAdOx1 nCoV-19, Animals, Antibodies, Viral, Immunization, Secondary, RNA, Viral, T-Lymphocytes, Cytotoxic, Vaccination, Vaccines, Synthetic, Th1 Cells, Mice, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review